Close Menu

    Subscribe to Updates

    Get the latest creative news from FooBar about art, design and business.

    What's Hot

    Air Arabia sets five weekly Sharjah Gdansk flights

    August 26, 2026

    EU expands Ebola response with €2.1 million PCR tests

    August 25, 2026

    Brent crude steadies after 2% drop amid Iran sanctions

    August 25, 2026
    • Home
    • Contact Us
    Armenia WatchArmenia Watch
    • Automotive
    • Business
    • Entertainment
    • Health
    • Lifestyle
    • Luxury
    • News
    • Sports
    • Technology
    • Travel
    Armenia WatchArmenia Watch
    Home » Innovative experimental malaria drug based on antibodies discovered
    Featured News

    Innovative experimental malaria drug based on antibodies discovered

    November 1, 2022
    Facebook WhatsApp Twitter Pinterest LinkedIn Telegram Tumblr Email Reddit VKontakte

    A new study in Africa has found that a one-time dose of an experimental drug protects adults against malaria for at least six months. In 2020, malaria killed more than 620,000 people and sickened 241 million, mostly children under 5. There is a malaria vaccine being rolled out by the World Health Organization for children, but it is only 30% effective and requires four doses.

    Innovative experimental malaria drug based on antibodies discoveredIn this new study, people received a large dose of lab-made malaria-fighting antibodies instead of relying on the immune system to make enough of those same infection-blockers after vaccination, reported the Associated Press (AP). “There are not enough people protected by the vaccine available,” said Kassoum Kayentao, a researcher from the University of Sciences, Techniques and Technologies in Bamako, Mali.

    In those villages, people are bitten by infected mosquitoes on average twice a day during malaria season, according to other research. Experimental antibody, developed by researchers at the US National Institutes of Health, was delivered by IV. In the meantime, an easy-to-administer shot version from the same scientists is in early testing in infants, children, and adults.

    Research presented at a medical meeting in Seattle was published Monday in the New England Journal of Medicine. In order to work, the antibody breaks the life cycle of the parasite, which is spread through mosquito bites. It targets immature parasites before they mature and multiply in the liver. An antibody taken from a volunteer who received a malaria vaccine was used to develop it.

    It involved 330 adults in Mali who received either a dummy infusion or two different antibody doses. Every two weeks for 24 weeks, all were tested for malaria infection. Treatment was provided to anyone who became ill. A blood test detected infections in 20 people who received the higher dose, 39 people who received the lower dose, and 86 people who received the placebo. Compared to the placebo, the higher dose was 88% effective. There was a 75% effectiveness rate for the lower dose.

    During a malaria season, protection might last for several months. In the future, it could be used in conjunction with other malaria prevention methods, such as malaria pills, mosquito nets, and vaccinations. According to one estimate, lab-made antibodies could be given for as little as $5 per child per malaria season.

    Related Posts

    STS Digital Launches Cross-Asset Portfolio Margin for Institutional Digital Asset Trading

    August 19, 2026

    Papa Johns teams up with Disney and Pixar for Toy Story 5

    August 7, 2026

    Talos Integrates with STS Digital to Bring Institutional Crypto Options and Spot Liquidity to its Provider Network

    August 5, 2026

    STS Digital Awarded Best Derivatives Trading Solution at TradingTech Insight Awards

    June 12, 2026

    STS DIGITAL JOINS GLOBAL ELITE WITH WEALTHBRIEFINGASIA AWARD

    May 29, 2026

    Silver tumbles as COMEX margins rise and volatility spikes

    February 14, 2026
    Latest News

    Air Arabia sets five weekly Sharjah Gdansk flights

    August 26, 2026

    EU expands Ebola response with €2.1 million PCR tests

    August 25, 2026

    Brent crude steadies after 2% drop amid Iran sanctions

    August 25, 2026

    South Korea starts first Arctic container ship trial

    August 24, 2026

    Alibaba raises HK$80 billion for AI and cloud growth

    August 24, 2026

    Australian team finds new way to tackle triple-negative breast cancer

    August 22, 2026

    Gulf nations deport nearly 22,000 Pakistanis in four months

    August 22, 2026

    DR Congo secures 70,000 doses for Ebola outbreak

    August 21, 2026
    © 2026 Armenia Watch | All Rights Reserved
    • Home
    • Contact Us

    Type above and press Enter to search. Press Esc to cancel.